Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Company aims for technology advancement and platform expansion with Korea's first influenza vaccine using an adjuvant Interim ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech' or 'the Company', HKEX: 6990) today announced that its partner, Windward Bio AG ('Windward Bio') has launched its Phase 2 POLARIS ...

Research and development collaboration program to include additional models of lymphoma and leukemia to further validate ...

Viatris reported that its MR-139 ophthalmic ointment failed to meet its primary endpoint in a Phase III blepharitis trial, while advancing its MR-141 and MR-142 candidates in presbyopia and night ...

Medpace beats Q2 2025 earnings, raises FY guidance, showcasing strong biotech demand. Click here to read an analysis of MEDP ...

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has granted Cipla Limited approval to conduct a Phase IV clinical trial of its ...

Property developers are circling prime sites being rezoned for high-density development to tackle the housing shortage on Sydney’s north shore. However, the demand for apartments has been superseded ...

Arch Biopartners Inc. ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the investigator-led Phase II trial titled "Prevention ...

One of the few drug trials for a possible long Covid ended in disappointment. But lessons are leading to a second chance.

Acute myocarditis is a potentially life-threatening condition affecting the heart muscle (myocardium) and is characterized by chest pain, shortness of breath, fatigue, rapid or irregular heartbeat ...

In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a ...